Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Crystal Proud

Neurology with Special Qualifications in Child Neurology Norfolk, VA Medical Doctor

NPI 1013159177 CMS profile 990357

850 Southampton Ave, Norfolk, VA 23510

Open in the dashboard

General payments

$1,001,986

854 records reported · program years 2019–2025

Research payments

$37,902

Paid to them · 31 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,088,517 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Crystal Proud of Norfolk, VA is reported in the CMS Open Payments database as having received $1,001,986 across 854 general payments and $37,902 in research payments paid to them. Separately, studies naming them as principal investigator received $6,088,517 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $279,590 119
2025 Research $11,520 5
2024 General $257,976 154
2024 Research $4,416 9
2023 General $155,435 166
2023 Research $2,728 7
2022 General $97,745 116
2022 Research $1,000 2
2021 General $53,518 61
2021 Research $13,737 7
2020 General $71,861 85
2019 General $85,861 153
2019 Research $4,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Crystal Proud
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Crystal Proud were reported at $279,590. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Crystal Proud Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $85,861 $262 $68–$1,313 $163
2020 $71,861 $188 $46–$1,222 $114
2021 $53,518 $183 $45–$1,356 $132
2022 $97,745 $229 $72–$1,177 $149
2023 $155,435 $269 $93–$1,195 $160
2024 $257,976 $300 $98–$1,428 $164
2025 $279,590 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $612,934 254 payments
  2. Biogen, Inc. $262,551 435 payments
  3. AveXis $68,287 95 payments
  4. F. Hoffmann-La Roche AG $21,752 9 payments
  5. Genentech USA, Inc. $9,805 9 payments
  6. Hoffmann-La Roche Limited $9,656 6 payments
  7. Pfizer Inc. $8,358 6 payments
  8. ITF Therapeutics LLC $5,044 11 payments
  9. Novartis Pharmaceuticals Corporation $2,581 5 payments
  10. Supernus Pharmaceuticals, Inc. $336 8 payments
  11. Other $681 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $663,626 135 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $177,614 122 payments
  3. Travel and Lodging $78,899 153 payments
  4. Honoraria $49,319 25 payments
  5. Food and Beverage $24,075 403 payments
  6. Education $8,454 16 payments
Products named General payments · program years 2019–2025
  1. SPINRAZA $212,665 359 payments
  2. ZOLGENSMA Gene Therapy $67,342 90 payments
  3. Skyclarys $21,864 25 payments
  4. Exondys 51 $19,514 19 payments
  5. Elevidys $16,346 15 payments
  6. Evrysdi $12,260 11 payments
  7. ZOLGENSMA Neurology $2,548 4 payments
  8. Zurzuvae $2,226 1 payment
  9. Qelbree $300 6 payments
  10. EMFLAZA $149 2 payments
  11. Other $407 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biogen, Inc. $12,500 2 payments
  2. Novartis Pharmaceuticals Corporation $9,908 2 payments
  3. Medtronic, Inc. $6,200 7 payments
  4. F. Hoffmann-La Roche AG $5,918 18 payments
  5. AveXis $3,164 1 payment
  6. Novartis Pharma AG $212 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

49

Median for Pediatric Medicine: 38

Drug cost

$289,883

Median for Pediatric Medicine: $2,769

Branded share of claims

22.4%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 11 $289,640
Fluoxetine Hcl Generic 13 $126
Prednisone Generic 13 $68
Baclofen Generic 12 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPINRAZA
  • Biogen, Inc. $13,290
$13,290 — —
Skyclarys
  • Biogen, Inc. $9,963
$9,963 — —
ZOLGENSMA
  • Novartis Pharmaceuticals Corporation $2,350
$2,350 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $217
$217 — —
QALSODY
  • Biogen, Inc. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

885 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record